Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oncotelic Therapeutics Inc
(OP:
OTLC
)
0.0375
UNCHANGED
Streaming Delayed Price
Updated: 1:37 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncotelic Therapeutics Inc
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
April 10, 2024
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
Via
News Direct
Topics
Death
Exposures
Death
Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
February 21, 2024
--News Direct--
Via
News Direct
Exposures
COVID-19
Oncotelic Therapeutics’ (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
October 11, 2023
--News Direct--
Via
News Direct
Exposures
COVID-19
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
October 10, 2023
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging.
Via
Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
September 27, 2023
--News Direct--
Via
News Direct
Exposures
COVID-19
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
September 25, 2023
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company.
Via
Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
September 13, 2023
--News Direct--
Via
News Direct
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
September 11, 2023
Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones,...
Via
Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Charge
September 11, 2023
Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones,...
Via
Benzinga
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
November 30, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
November 16, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
November 08, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
October 12, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Announces Formation of Animal Health Division
October 06, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
September 28, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
May 28, 2022
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...
Via
Talk Markets
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
December 14, 2021
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
Via
News Direct
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
November 23, 2021
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
Via
News Direct
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.